Clik here to view.
OPKO Lab Signs Contracts with Leading Preferred Provider Networks for...
MIAMI, Aug 19, 2015 (BUSINESS WIRE) -- OPKO Health, Inc. OPK, -0.24% today announced that it has entered into agreements with Stratose, Three Rivers Provider Network and Fortified Provider Network for...
View ArticleClik here to view.
Dr. Frost Discusses Bio-Reference Acquisition, Impact of 4Kscore Test with...
OPKO Health CEO Dr. Phillip Frost visited Jim Cramer on Mad Money September 25, 2015, to explain the recent acquisition of Bio-Reference Laboratories and the impact it expects to have on our overall...
View ArticleClik here to view.
Opko Health Research Coverage Started at JPMorgan Chase & Co. (OPK)
Article Published in the Dakota Financial News, October 16, 2015
View ArticleClik here to view.
4Kscore Might Reduce Unnecessary Prostate Biopsies
ORLANDO—The 4Kscore, an algorithmic analysis of data from a blood test that combines four kallikrein assays with clinical information to identify the probability of high-grade prostate tumors, could...
View ArticleClik here to view.
Study Confirms 4Kscore Accurately Predicts High-Grade Prostate Cancer
By Anna Azvolinsky, PhD
View ArticleClik here to view.
New Blood Test Helps You Avoid Unnecessary Prostate Cancer Biopsies
Can be used in conjunction with PSA blood testMay 6, 2015 / By Urinary & Kidney Team at Cleveland Clinic
View ArticleClik here to view.
New Test Reducing The Number Of Invasive Prostate Biopsies
MIAMI (CBSMiami) – Every year more than one million men have a prostate biopsy, an invasive procedure that involves needles. It turns out a majority of those biopsies reveal if a patient has no...
View ArticleClik here to view.
Study Demonstrates OPKO's 4Kscore Test Reduces Unnecessary Prostate Biopsies...
4Kscore Test Results Significantly Influenced Physician-Patient Shared Decision-Making in Clinical Practice and Led to a 64.6% Reduction in Prostate Biopsies
View ArticleClik here to view.
OPKO Announces Publication of Study Using Kallikrein Biomarkers of the...
MIAMI--(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced the online publication of a study entitled "A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in...
View ArticleClik here to view.
New Blood Test Helps You Avoid Unnecessary Prostate Cancer Biopsies
Can be used in conjunction with PSA blood testA new screening tool for prostate cancer has been shown to offer better accuracy than the test currently used by most physicians in the United States. The...
View Article